# Agonism of DR3 for Enhanced Treg Cell Function in IBD

> **NIH NIH F30** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2020 · $38,786

## Abstract

PROJECT SUMMARY
The immune-mediated, chronic inflammation in inflammatory bowel disease (IBD) leads to flares that often
require patients to be treated with life-long biologic therapy. Recently, efforts in IBD disease management have
focused on the potential of regulatory T (Treg) cell-based therapy as an alternative to traditional treatments. Treg
cells limit inflammatory responses to both foreign and self-antigens and can become further differentiated into
potently suppressive effector Tregs (eTregs) upon exposure to immune stimuli. eTregs, especially those that
produce the immunosuppressive cytokine interleukin 10 (IL-10), play a critical, mitigating role in both human and
murine colitis. However, the signals that induce and functionally enhance this subset are not well understood,
largely because they are limited in number and there have been no suitable protocols to differentiate them in
vitro. Here, we have identified a signal that enhances the expansion and maintenance of IL-10+ eTregs in vivo
and in vitro. Death receptor 3 (DR3 or TNFRSF25) is a tumor necrosis factor receptor superfamily (TNFRSF)
member that is constitutively expressed by activated T cells and has been found to both enhance and suppress
the immune response. We have found that treatment with an agonist antibody to DR3 (aDR3) significantly
enhances the proliferation and cell survival specifically of IL-10+ eTregs. Additionally, treatment greatly expands
total Treg cells in many tissues, but the effect is most profound in the intestine. To our knowledge, the observation
that aDR3 expands IL-10 producing eTregs has not yet been described. This proposal will determine the
mechanisms by which DR3 signaling induces increased intestinal Tregs (Aim 1), as well as the potential of aDR3
as a therapeutic in the treatment of colitis (Aim 2). We will utilize a novel transgenic mouse model that lacks DR3
specifically in Tregs to understand the role that DR3 signaling plays in intestinal Treg function in both the steady
state and in the inflamed colon. By using our IL-10 and Foxp3 dual reporter mouse, we will be able to stratify
Treg populations by IL-10 competency, which will allow us to characterize the mechanisms by which DR3
differentially enhances Treg cell subsets. Our central hypothesis is that the effect of DR3 signaling is two-fold in
that it: (1) primes Treg cells for an effector phenotype; and (2) enacts a specific program that impacts eTreg
survival, stability, and function. Understanding how this pathway augments Treg cell function will have broad-
reaching implications not only in the field of IBD, but also in the management of a number of immune-mediated
diseases.

## Key facts

- **NIH application ID:** 9872895
- **Project number:** 5F30DK121398-02
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Emma C Dean
- **Activity code:** F30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $38,786
- **Award type:** 5
- **Project period:** 2019-02-01 → 2023-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9872895

## Citation

> US National Institutes of Health, RePORTER application 9872895, Agonism of DR3 for Enhanced Treg Cell Function in IBD (5F30DK121398-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9872895. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*